FDx Advisors’s NeoGenomics NEO Stock Holding History

FDx Advisors’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-30,644	Closed	-$250K	–	1013
2018 Q1	$250K	Buy	30,644 +5,091	+20%	+$41.2K	0.01%	1054
2017 Q4	$226K	Buy	25,553 +2,524	+11%	+$23.3K	0.01%	1150
2017 Q3	$256K	Buy	23,029 +6,306	+38%	+$61.4K	0.01%	1099
2017 Q2	$150K	Buy	+16,723	New	+$133K	﹤0.01%	1156

Other funds holding NEO

General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

GIP

Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return

FDx Advisors's NEO Position: Q2 2018 in Review

FDx Advisors sold out of NeoGenomics (NEO) in Q2 2018, closing a stake of 30,644 shares — an estimated $250K sold.

FDx Advisors first reported a position in NEO in Q2 2017 and held it in 4 quarters. The position peaked at $256K in Q3 2017. 147 funds tracked by Wall St. Rank hold NEO as of Q2 2018.

FDx Advisors reported no remaining NeoGenomics position as of Q2 2018 after selling out during the quarter.
FDx Advisors sold 30,644 NeoGenomics shares in Q2 2018, an estimated $250K.
FDx Advisors first reported a position in NeoGenomics in Q2 2017 and held it in 4 quarters.
FDx Advisors's NeoGenomics position peaked at $256K in Q3 2017.
147 funds tracked by Wall St. Rank held NeoGenomics as of Q2 2018.

Based on FDx Advisors's 13F filing for Q2 2018, filed 8 Aug 2018.